Antisense and RNAi therapeutics are new innovative therapeutics options that are used in the treatment of serious chronic and rare diseases. RNAi is a RNA-based gene silencing process in which RNA molecules inhibit gene expression by destructing definite mRNA molecules. Antisense technology involves the synthesis of a strand of nucleic acid that would bind to an mRNA or to a splicing site on pre-mRNA and inactivates it effectively. RNAi and antisense are two predominant technologies used by pharmaceutical companies, research institutes, and others for various applications such as research, diagnostics, and therapeutics. RNAi therapeutics have a large scope in the treatment of diseases such as cancer and neurodegenerative disorders. There are two types of RNA molecules used in the RNAi technology: miRNA and siRNA.

TechNavio’s analysts forecast the Global Antisense and RNAi Therapeutics market to grow at a CAGR of 26.79 percent over the period 2014-2019.

Covered in this Report

This report covers the present scenario and the growth prospects of the Global Antisense and RNAi Therapeutics market for the period 2015-2019. To calculate the market size, the report considers the revenue generated from the sales of antisense and RNAi therapeutics used for the treatment of various serious chronic diseases including:

• Infectious diseases
• Cardiovascular diseases
• Kidney diseases
• Cancer
• Metabolic disorders
• Others

The report also covers the two main technologies, i.e., Antisense and RNAi technology, which are used by vendors to develop antisense and RNAi therapeutics.

TechNavio’s report, the Global Antisense and RNAi Therapeutics Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Antisense and RNAi Therapeutics market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Key Regions

• Americas
• APAC
• EMEA

Key Vendors

• Alnylam Pharmaceuticals
• Isis Pharmaceuticals
• Sanofi
• Tekmira Pharmaceuticals

Other Prominent Vendors

• Acuitas Therapeutics
• Allergan
• Antisense Therapeutics
• Ascletis
• AstraZeneca
• Atlantic Pharmaceuticals
• Benitec Biopharma
• Biogen Idec
• Bristol-Myers Squibb
• Dainippon Sumitomo Pharma
• Dicerna Pharmaceuticals
• Enzon Pharmaceuticals
• F. Hoffmann-La Roche
• Glaxosmithkline
• Gradalis
• iCo Therapeutics
• Kyowa Hakko Kirin
• Marina Biotech
• Novartis
• OncoGenex Pharmaceuticals
• OPKO Health
• Pfizer
• Quark Pharmaceuticals
• Regulus Therapeutics
• Silence Therapeutics
• Spectrum Pharmaceuticals
• Sylentis
• Takeda Pharmaceutical
• Teva Pharmaceutical
• The Medicines Company
• TransDerm

Market Driver

• Advances in Technology
• For a full, detailed list, view our report

Market Challenge

• Toxicity of Antisense and RNAi Molecules-based Drugs
• For a full, detailed list, view our report

Market Trend

• Increased Strategic Collaborations and Licensing Activities
• For a full, detailed list, view our report

Key Questions Answered in this Report

• What will the market size be in 2018 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

Table of Contents

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report
03.1 Market Overview
03.2 Product Offerings

04. Market Research Methodology
04.1 Market Research Process
04.2 Research Methodology

05. Introduction

06. Market Landscape
06.1 Market Overview
06.2 Market Size and Forecast
06.3 Five Forces Analysis

07. Market Segmentation by Technology

08. Market Segmentation by Therapeutics Area

09. Geographical Segmentation
09.1 Antisense and RNAi Therapeutics Market in Americas
09.1.1 Market Size and Forecast
09.2 Antisense and RNAi Therapeutics Market in EMEA Region
09.2.1 Market Size and Forecast
09.3 Antisense and RNAi Therapeutics Market in APAC Region
09.3.1 Market Size and Forecast

10. Buying Criteria

11. Pipeline Snapshot

12. Market Growth Drivers

13. Drivers and their Impact

14. Market Challenges

15. Impact of Drivers and Challenges

16. Market Trends

17. Trends and their Impact

18. Vendor Landscape
18.1 Competitive Scenario
18.1.1 Key News
18.1.2 Mergers and Acquisitions and Collaborations
18.2 Vendor Analysis 2014
18.3 Other Prominent Vendors

19. Key Vendor Analysis
19.1 Alnylam Pharmaceuticals
19.1.1 Key Facts
19.1.2 Business Overview
19.1.3 Financial Performance
19.1.4 Recent Developments
19.1.5 SWOT Analysis
19.2 Isis Pharmaceuticals
19.2.1 Key Facts
19.2.2 Business Overview
19.2.3 Revenue Comparison 2011 and 2013
19.2.4 Recent Developments
19.2.5 SWOT Analysis
19.3 Sanofi SA
19.3.1 Key Facts
19.3.2 Business Description
19.3.3 Business Segmentation
19.3.4 Revenue by Business Segmentation
19.3.5 Revenue Comparison 2012 and 2013
19.3.6 Sales by Geography
19.3.7 Business Strategy
19.3.8 Key Developments
19.3.9 SWOT Analysis
19.4 Tekmira Pharmaceuticals
19.4.1 Key Facts
19.4.2 Business Overview
19.4.3 Financial Performance
19.4.4 Key Developments
19.4.5 SWOT Analysis

20. Other Reports in this Series

List of Exhibits:

Exhibit 1: Market Research Methodology
Exhibit 2: Global Antisense and RNAi Therapeutics Market 2014-2019 (US$ million)
Exhibit 3: Global Antisense and RNAi Therapeutics Market Segmentation by Technology
Exhibit 4: Global Antisense and RNAi Therapeutics Market Segmentation by Technology 2014
Exhibit 5: Global Antisense and RNAi Therapeutics Market by Therapeutics Area
Exhibit 6: Global Antisense and RNAi Therapeutics Market by Geographical Segmentation 2014
Exhibit 7: Antisense and RNAi Therapeutics Market in Americas 2014-2019 (US$ million)
Exhibit 8: Antisense and RNAi Therapeutics Market in EMEA Region 2014-2019 (US$ million)
Exhibit 9: Antisense and RNAi Therapeutics Market in APAC Region 2014-2019 (US$ million)
Exhibit 10: Global Antisense and RNAi Therapeutics Market by Geographical Segmentation 2014-2019 (US$ million)
Exhibit 11: Global Antisense and RNAi Therapeutics Market by Geographical Segmentation 2014-2019
Exhibit 12: Alnylam Pharmaceuticals: Financial Performance 2013-2012 (in million)
Exhibit 13: Isis Pharmaceuticals: Revenue Comparison 2011 and 2013(US$ million)
Exhibit 14: Sanofi SA: Business Segmentation
Exhibit 15: Sanofi SA: Revenue by Business Segmentation 2013
Exhibit 16: Sanofi SA: Revenue by Business Segmentation 2012 and 2013 (US$ million)
Exhibit 17: Sanofi SA: Sales Revenue by Geographical Segmentation 2013
Exhibit 18: Tekmira Pharmaceuticals: Financial Performance 2012-2013